摘要
可改善转移性耐去势前列腺癌患者总生存期的新药物的有效性,使得使用它们提高累计存活率成为可能。这种新的药物已被管理作为第三线治疗药物,而之前它们被当作二线药物。但其疗效还没有得到临床试验数据的证明,使用最佳序列以最大限度地提高治疗效果的交叉耐药性已经得到证实。此外,把新的激素药物应用于化疗患者以及把新的化疗药物应用于激素敏感者使得情况更加复杂。本文批判性地总结讨论了有关连续使用新药物的数据,并讨论了他们在治疗转移性耐去势前列腺癌的最佳定位。
关键词: 耐去势前列腺癌,序列,一线药物,二线药物,多烯紫杉醇,醋酸阿比特龙,cabazitaxel, enzalutamide
图形摘要
Current Drug Targets
Title:Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?
Volume: 17 Issue: 11
Author(s): Orazio Caffo, Andrea Lunardi, Chiara Trentin, Francesca Maines, Antonello Veccia, Enzo Galligioni
Affiliation:
关键词: 耐去势前列腺癌,序列,一线药物,二线药物,多烯紫杉醇,醋酸阿比特龙,cabazitaxel, enzalutamide
摘要: The availability of new drugs capable of improving the overall survival of patients with metastatic castration-resistant prostate cancer has led to the possibility of using them sequentially in the hope of obtaining a cumulative survival benefit. The new agents have already been administered as third-line treatments in patients who have previously received them as second line in everyday clinical practice, but the efficacy of this practice is not yet supported by clinical trial data, and evidence of possible cross-resistance has reinforced the debate concerning the best sequence to use in order to maximise the benefit. Furthermore, the situation is further complicated by the possibility of administering new hormonal agents to chemotherapy-naïve patients, and novel chemotherapeutic agents to hormone-sensitive patients. This article critically reviews the available data concerning the sequential use of new drugs, and discusses the real evidence concerning their optimal positioning in the therapeutic strategy of metastatic castration-resistant prostate cancer.
Export Options
About this article
Cite this article as:
Orazio Caffo, Andrea Lunardi, Chiara Trentin, Francesca Maines, Antonello Veccia, Enzo Galligioni , Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?, Current Drug Targets 2016; 17 (11) . https://dx.doi.org/10.2174/1389450117666160101121317
DOI https://dx.doi.org/10.2174/1389450117666160101121317 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer
Current Pharmaceutical Biotechnology Role of NUCB2/nesfatin-1 as a Possible Biomarker
Current Pharmaceutical Design Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design PET Tracers for Serotonin Receptors and Their Applications
Central Nervous System Agents in Medicinal Chemistry Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry Antibody Gene Therapy: Getting Closer to Clinical Application?
Current Gene Therapy Thyroid Hormone Treatment for Differentiated Thyroid Carcinoma: What Drug, How Long, What Dose?
Current Cancer Therapy Reviews The Characteristics, Functions and Inhibitors of Three Aminopeptidases Belonging to the M1 Family
Current Protein & Peptide Science Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Stereological Quantification of Blood and Lymph Microvessels in Prostate Cancer. Its Relevance for the Anti-angiogenetic Therapy
Current Cancer Therapy Reviews Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Pathogenic Role of Serine Protease HtrA2/Omi in Neurodegenerative Diseases
Current Protein & Peptide Science Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment
Current Drug Safety A Review on Chemical Profile of Coumarins and their Therapeutic Role in the Treatment of Cancer
Current Drug Delivery Differential Involvement of Myosin II and VI in the Spontaneous and SDF- 1-induced Migration of Adult CD133+ Hematopoietic Stem/Progenitor Cells and Leukemic Cells
Current Cancer Therapy Reviews Editorial (Thematic issue: Discovering New Anticancer Activities from Old Drugs)
Current Medicinal Chemistry Cancer-Specific Ligands Identified from Screening of Peptide-Display Libraries
Current Pharmaceutical Design 5-Lipoxygenase: A Promising Drug Target Against Inflammatory Diseases-Biochemical and Pharmacological Regulation
Current Drug Targets ETS Proteins and MMPs: Partners in Invasion and Metastasis
Current Drug Targets Pharmacomimetics of Exercise: Novel Approaches for Hippocampally- Targeted Neuroprotective Agents
Current Medicinal Chemistry